資源描述：
《復(fù)方牛胎肝提取物治療乙型肝炎肝硬化療效觀察》由會(huì)員上傳分享，免費(fèi)在線閱讀，更多相關(guān)內(nèi)容在工程資料-天天文庫。
1、復(fù)方牛胎肝提取物治療乙型肝炎肝硬化療效觀察盧敏，毛華，黃純熾，唐銀麗，張能友，席建東【摘要】口的探討復(fù)方牛胎肝提取物治療乙型肝炎肝硬化患者的療效。方法將120例乙型肝炎肝駛化患者隨機(jī)分為治療組80例和對(duì)照組40例。給予治療組復(fù)方牛胎肝聯(lián)合基礎(chǔ)護(hù)肝治療，對(duì)照組僅予以基礎(chǔ)護(hù)肝治療，療程3個(gè)月，對(duì)比兩組患者治療前后肝功能、肝臟硬度值(LSM),以及B超檢測(cè)門靜脈內(nèi)徑、脾臟厚度、脾靜脈寬度的變化。結(jié)果在3個(gè)刀治療結(jié)束時(shí)，治療組患者血清TBIL為(33.0±2.07)pnol/L、ALT為(3640±5.86)U/L、LSM為(1
2、0.78±1.15)Kpa,均較對(duì)照組顯著下降[分別為(48.62±4.24)pmol/L、(52.60±7.3)U/L、(15.26±2.17)Kpa,P<0.05];治療組血清ALB水平為(35.0±1.58)g/L,較對(duì)照組明顯升高[(31±1.58)g/L,PV0.05];治療組門靜脈內(nèi)徑為(1.26±0.08)cm,脾臟厚度為(3.97±0.04)cm，脾靜脈寬度為(0.87±0.02)cm,均較對(duì)照組顯著降低[分別為(1.36±0.05)cm、(4.20±0.10)cm、(0?92±0?02)cm,P<0.0
3、5]。結(jié)論復(fù)方牛胎肝提取物可顯著改善乙型肝炎肝駛化患者的肝功能，減輕肝纖維化程度?！娟P(guān)鍵詞】肝硬化;乙型肝炎;復(fù)方牛胎肝提取物;療效DOI：10.3969/j.issn.l672-5069.2015.02.011EfficacyofcompoundembryonicbovineliverextractinpatientswithhepatitisBrelatedlivercirrhosisLuMin,MaoHua,HuangChunchi,etal.DepartmentofGastroenterology,Zhujian
4、gHospitalAffiliatedtoSouthernMedicalUniversity,Guangzhou510282,GuangdongProvince,China[Abstract]ObjectiveToinvestigatetheeffectofcompoundembryonicbovineliverextractinpatientswithhepatitisBrelatedlivercirrhosis.MethodsOnehundredandtwentypatientswithhepatitisBinduc
5、edlivercirrhosiswererandomlydividedintotwogroups,with80intreatmentgroupreceivingcompoundembryonicbovineliverextracttabletsatthebaseofbasicliver-protectingtreatmentand40incontrolgroupreceivingthebasicliv-er-protectingtreatmentonlyfor3months.Liverfunctiontests,live
6、rstiffnessmeasurement(LSM)byFibrotouch,andportalveindiameters,spleenthicknessandsplenicveinwidthbeforeandaftertreatmentwerecomparedinbothgroups?ResultsAttheendof3-monthtreatment,scrumTBIL,ALT,andLSMvaluesinpatientsintreatmentgroupwere(33.0±2.07)(imol/L,(36.40±5.8
7、6)U/L,(10.78±1.15)Kpa,respectively,significantlydecreasedascomparedwiththoseinthecontrols[(48.62±4.24)pmol/L,(52.60±7.3)U/L,(15.26±2」7)Kpa，respectively,P<0.05forall];serumALBlevelsinpatientsintreatmentgroupincreasedsignificantlycomparedwiththatincontrols[(35.0±1.
8、58)g/Lvs.(31±1?58)g/L,P<0.05];portalveindiameters,spleenthicknessandsplenicveinwidthsremarkablydecreasedcomparedwiththoseinpatientsinthecontrolgroup[(1.26±0.08
